Welcome to our dedicated page for Aimfinity Investment I Unit SEC filings (Ticker: AIMAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aimfinity Investment I Unit's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aimfinity Investment I Unit's regulatory disclosures and financial reporting.
Aimfinity Investment Corp. I entered into an unsecured promissory note for $55,823.8 on August 28, 2025 with I-Fa Chang, a member and manager of its sponsor, to fund a new monthly extension payment into the company’s trust account. This payment extends the deadline to complete its previously approved business combination with Docter Inc. by one month, from August 28, 2025 to September 28, 2025, and represents the eighth of up to nine monthly extensions allowed under its charter.
Under the note and an earlier exchange agreement, any unpaid balance will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share when the business combination with Docter closes. The note was issued as an unregistered security relying on the private offering exemption in Section 4(a)(2) of the Securities Act, and the company also issued a press release announcing the new extension.
Aimfinity Investment Corp I (AIMAU) filed an 8-K furnishing updated unaudited pro forma condensed combined financials for its pending merger with Docter Inc.
- Shareholders approved the Business Combination at the 27 Mar 2025 extraordinary general meeting.
- 1,072,957 Class A shares were redeemed; the pro forma schedules now reflect the actual cash outflow and reduced public float.
- Updates incorporate conversion of extension and working-capital loans, Docter promissory notes, discharge agreements and a 12-month burn-rate estimate.
- The deal will be accounted for as a reverse recapitalization; Docter holders will control the post-close vehicle, renamed “Inkwater Holding”.
- Base scenario assumes no warrant exercises and no earn-out shares, providing a clean view of initial ownership and capital structure.
The filing supplies investors with revised balance sheet, ownership table and key transaction accounting adjustments, but excludes synergy forecasts.